Compare AbCellera Biologics Inc (ABCL) vs Coursera Inc (COUR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Coursera Inc — how do they compare? AbCellera Biologics Inc trades at $7.22 (market cap $2.35B), while Coursera Inc trades at $5.83 (market cap $1.66B). The key difference: AbCellera Biologics Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Coursera Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | COUR | |
|---|---|---|
Market Cap | $2.35B | $1.66B |
Sector | Health | Consumer Staples |
52-Week High | $8.12 | $12.70 |
52-Week Low | $2.78 | $5.09 |
Enterprise Value | $1.99B | $915.98M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
Coursera (COUR) trades at $5.80, down 1.69% today, with a bullish technical signal from moving averages. Revenue grew to $757.5M in 2025, though net income remains negative at -$51M. The company completed its merger with Udemy in May 2026, aiming for synergies, and announced a $500M share repurchase program. Positive cash flow from operations of $108.7M supports financial stability.
The outlook is mixed: analyst consensus targets $8.00 (37.9% upside), with 53% buy ratings, but persistent losses and competitive pressures pose risks. Earnings misses in recent quarters highlight execution challenges. The stock offers growth potential via market expansion and merger benefits, yet profitability concerns and market volatility require cautious evaluation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Coursera Inc
Coursera Inc is a global online learning platform that offers anyone, anywhere access to online courses and degrees from world-class universities and companies. It combines content, data, and technology into a single, unified platform that is customizable and extensible to both individual learners and institutions. The platform will contain a catalog of high-quality content and credentials, content developed by leading university and industry partners, data and machine learning drive personalized Learning, effective marketing, and skills Benchmarking and others.
Read more on COUR →
